drugset / Trial / NCT03342638
Maximizing Outcome of Multiple Sclerosis Transplantation
RandomizedParallel-groupOpen-labelTreatment
Summary
Randomized study of autologous un-manipulated peripheral blood hematopoietic stem cell transplant (HSCT) comparing two regimens: (1) cyclophosphamide and rabbit anti-thymoglobulin (rATG) versus (2) cyclophosphamide, rATG, and Intravenous Immunoglobulin (IVIg).
Timeline
- Start
- 2017-11-08
- Primary completion
- 2019-07-23
- Completion
- 2019-10-09
Outcome
Outcome not reported
Stopped: “PI Sabbatical”
Drugs
| Evaluation | Drug | Modality | Dose | Route |
|---|---|---|---|---|
| Subject | Immune Globulin Intravenous (Human) | Protein / enzyme biologic | — | — |
| Background | 2-MERCAPTOETHANESULFONIC ACID | Small molecule | — | — |
| Background | Autologous Stem Cells | Cell therapy | — | — |
| Background | Cyclophosphamide | Other / unclassified | — | — |
| Background | G-CSF | Protein / enzyme biologic | — | — |
| Background | Methylprednisolone | Other / unclassified | — | — |
| Background | rATG | Protein / enzyme biologic | — | — |